Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02520713 · ClinicalTrials.gov registry record
The iCat2, GAIN (Genomic Assessment Informs Novel Therapy) Consortium Study
A clinical trial of Pediatric Solid Tumor, sponsored by Dana-Farber Cancer Institute.
- Active
- Registry status
- 825
- Enrollment target
- 12
- Study locations
NCT02520713: Active study of Pediatric Solid Tumor, sponsored by Dana-Farber Cancer Institute.
NCT02520713 is a study of Pediatric Solid Tumor that is active but no longer recruiting, run by Dana-Farber Cancer Institute. The registered enrollment target is 825 participants, below the 1,050-participant average among 10 other Pediatric Solid Tumor trials with a reported enrollment target (21% lower). The trial reports 12 study locations across 11 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02520713, a study of Pediatric Solid Tumor, is active but no longer recruiting, sponsored by Dana-Farber Cancer Institute.
- ACTIVE NOT RECRUITING
- Registry status
- 825 participants
- Enrollment target
- 12
- Study locations
Study Summary
This research study is evaluating the use of specialized testing of solid tumors including sequencing. The process of performing these specialized tests is called tumor profiling. The tumor profiling may result in identifying changes in genes of the tumor that indicate that a particular therapy may have activity. This is called an individualized cancer therapy (iCat) recommendation. The results of the tumor profiling and, if applicable, the iCat recommendation will be returned.
Primary Outcome
In pediatric patients with recurrent or refractory solid tumors who undergo successful molecular profiling, a) to describe the overall survival of patients by treatment group (iCatM, iCatUM and UM); b) to identify demographic, clinical, and genomic factors associated with overall survival from the time of relapse/progression (OSr); and c)to store tumor material, derived cell lines / xenografts, and blood samples for general sample banking and potential future research.
Conditions Studied
Interventions
- GENETIC Genetic testing and GAIN report
Study Locations (12)
Massachusetts
- Boston Children's Hospital - Boston
- Dana-Farber Cancer Institute - Boston
California
- University of California San Francisco - San Francisco
Colorado
- Children's Hospital Colorado - Aurora
District of Columbia
- Children's National Medical Center - Washington D.C.
Illinois
- University of Chicago Comer Children's Hospital - Chicago
New York
- Columbia University Medical Center - New York
Ohio
- Nationwide Children's Hospital - Columbus
Pennsylvania
- Children's Hospital of Philadelphia - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 825 participants |
| Start Date | 2015-10 |
| Est. Completion | 2026-10 |
What the registry record for NCT02520713 still lists
NCT02520713 is an observational study that tracks outcomes without assigning an intervention. The registered 825 participants enrollment target is mid-sized for trials with a published cap, below the 1,050-participant average among 10 other Pediatric Solid Tumor trials with a reported enrollment target (21% lower).
The record links to 1 condition, with Pediatric Solid Tumor appearing as the primary indexed condition, and to 1 intervention - of which Genetic testing and GAIN report is the first listed.
NCT02520713 lists 12 locations in 11 states (Massachusetts, California, Colorado).
Frequently Asked Questions
What is clinical trial NCT02520713 about?
NCT02520713 is a clinical study titled "The iCat2, GAIN (Genomic Assessment Informs Novel Therapy) Consortium Study". This research study is evaluating the use of specialized testing of solid tumors including sequencing. The process of performing these specialized tests is called tumor profiling. The tumor profiling may result in identifying changes in genes of the tumor that indicate that a particular therapy may ...
What is the current status of trial NCT02520713?
This trial is currently active not recruiting. The enrollment target is 825 participants. The study started on 2015-10. Estimated completion is 2026-10.
What conditions does trial NCT02520713 study?
This clinical trial studies the following conditions: Pediatric Solid Tumor.
What interventions are being tested in trial NCT02520713?
The interventions under investigation include: Genetic testing and GAIN report (GENETIC).
Who is sponsoring clinical trial NCT02520713?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02520713 being conducted?
This trial has 12 study locations across California, Colorado, District of Columbia, Illinois, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pediatric Solid Tumor
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02520713's enrollment target sits among peer trials
825 2nd of 10 the highest of 10 other Pediatric Solid Tumor trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Pediatric Solid Tumor trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
B7-H3-Specific Chimeric Antigen Receptor Autologous T-Cell Therapy for Pediatric Patients With Solid Tumors (3CAR)
RECRUITING · Phase 1
-
Safety and Efficacy of Cyclophosphamide, Sorafenib, Bevacizumab, and Atezolizumab in Pediatric Solid Tumor Patients
RECRUITING · Phase 1
-
Metarrestin (ML-246) in Subjects With Metastatic Solid Tumors
RECRUITING · Phase 1
-
Targeting Pediatric Brain Tumors and Relapsed/Refractory Solid Tumors With Sodium Glucose Cotransporter 2 Inhibitors (SGLT2i)
RECRUITING · Phase 1
-
Natural History and Biospecimen Acquisition for Children and Adults With Rare Solid Tumors
RECRUITING
-
B7H3 CAR T Cell Immunotherapy for Recurrent/Refractory Solid Tumors in Children and Young Adults
ACTIVE NOT RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05630482 · 825 participants · NA
Randomized Trial of Healthy Family Foundations
- NCT06097728 · 825 participants · Phase 3
MEDI5752 in Combination With Carboplatin Plus Pemetrexed in Unresectable Pleural Mesothelioma
- NCT07102641 · 825 participants · Phase 4
Post-cesarean Analgesia: Comparing Effectiveness of Staggered v. Simultaneous Therapies
- NCT07318077 · 825 participants · NA
Radicle GI Health DBG: A Study Assessing the Impact of Health and Wellness Products on GI Health and Related Health Outcomes
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia